Pharma and biotech hiring in 2026: The challenges, the hardest-to-fill roles, and the funding reality

In our experience, the hiring leaders who are succeeding in 2026 have stopped reading the market as a single signal. They recognise that the layoff narrative and the talent shortage narrative are both true, applied to different roles and different segments. Big pharma can absorb cuts that would be existential for a Series B biotech. A computational chemist available because their AI biotech failed a Phase II is not the same as a senior regulatory leader who has been with their company for fifteen years. From what we see across hiring processes, companies that still treat the market as either 'hot' or 'cold' are paying for that simplification with delayed hires, missed candidates, and offers that arrive at the wrong number.

Five challenges sit on most hiring leaders' desks in 2026, and they interact in ways that make any single solution insufficient.

• The first is the candidate caution problem. After three years of high-profile layoffs at Novo Nordisk, Bayer, Bristol Myers Squibb, Moderna, and dozens of mid-cap biotechs, candidates evaluating moves are running noticeably more due diligence than they did in 2022. They are asking about cash runway, clinical milestone risk, and the specific track record of leadership through previous downturns. The strongest candidates are willing to consider moves, but they are slower to commit, and offers that would have closed in two weeks in 2021 now routinely take six to eight.
  
  
• The second is the funding-driven volatility within individual companies. A biotech that is hiring aggressively in March can be running a hiring freeze by August if a clinical readout misses or a Series C closes at a lower valuation than expected. We consistently see clients underestimate how often their own hiring authority changes between when a search opens and when it closes. The hiring managers who succeed in 2026 are those who build flexibility into their search timelines and are honest with candidates about funding cycles.
  
  
• The third is the specialist-versus-generalist split. Job postings overall are down. BioSpace data showed approximately 8% fewer postings year-on-year in early 2025. But for specific specialist roles (regulatory affairs, AI/computational, advanced therapy CMC, and market access for rare diseases), hiring is up and competition is intense. Companies that staff their searches assuming a single market dynamic miss this. They expect specialists to be plentiful because the market 'feels' soft, then discover they are competing against four other employers for the same shortlist.
  
  
• The fourth is the AI and digital literacy gap. ABPI has reported 43% of pharma companies struggle to find candidates with the digital literacy skills now required across the workforce. The gap exists partly because traditional life sciences degrees still under-cover computational and data skills, and partly because AI-native employers (Isomorphic Labs, Recursion, Insilico, Xaira) have built strong pulls on the strongest candidates. Pharma companies that have not developed their own credible AI roadmap struggle to compete for the talent needed to build one.
  
  
• The fifth is the European cluster competition. Life sciences hiring in Europe concentrates heavily in Basel, Cambridge-Oxford-London, Amsterdam, Mainz, Munich, Heidelberg, Copenhagen, and Dublin. Within those clusters, every major employer recruits from the same pool. Cross-cluster recruiting has become aggressive. A senior pharmacovigilance physician in Basel is being approached simultaneously by every major pharma in Switzerland and several in Germany. The companies winning these candidates are running searches across all clusters, not just their home market.

Six categories carry the most weight in 2026 hard-to-fill European searches. The pattern is consistent across our practice and across the published market intelligence: these are the roles where supply has structurally fallen behind demand, and the gap is widening rather than closing.

• Senior CMC Leaders for Cell and Gene Therapy are arguably the single most contested profile in European life sciences in 2026. Demand for Directors and Vice Presidents of Chemistry, Manufacturing, and Controls with cell therapy or viral vector manufacturing experience has exceeded supply by approximately 4-to-1 since 2023. The advanced therapy pipeline emerging from VIB spin-offs in Belgium, the Cambridge cell therapy cluster, and the German ATMP work has compounded the shortage. These searches routinely take 6 to 9 months, even at strong total package levels.
  
  
• AI-Aware Regulatory Affairs and Quality Leaders have moved from a niche speciality to a category-defining hire in 2026. The combination of the EU AI Act high-risk obligations effective August 2026, the EMA's expanded Annex 11 and new Annex 22 on AI in GMP, and the FDA-EMA joint AI guiding principles published in January 2026 has created a regulatory framework that very few candidates can credibly navigate. We consistently see clients struggle to find regulatory leaders who can confidently sign off on AI-enabled processes. The candidates who can are the most strategically valuable hires of the year
  .
• Qualified Persons for Pharmacovigilance (QPPVs) remain among the longest-running senior-level shortages in European pharma. The role requires a medical or pharmacy degree combined with a decade or more of senior PV leadership and personal regulatory accountability for the company's entire pharmacovigilance system. With Regulation (EU) 2025/1466 effective from August 2025 and the GVP Module IX overhaul expected in Q2 2026, demand has continued to rise. QPPV searches take longer to close than any other PV role in our practice.
• 
  Computational Biologists and ML Scientists for Drug Discovery are critical to every meaningful pharma AI roadmap, and the companies pulling the strongest candidates are the AI-native biotechs (Isomorphic Labs, Recursion, Insilico, Xaira) plus the big pharma AI labs that have built credible scientific teams. Pure ML candidates without a biology context struggle to land senior roles in this market. The most contested profiles are PhDs with five-plus years of practical experience at the intersection of computation and biology.
  
  
• Market Access and HEOR Leaders for Rare Disease and Advanced Therapy are increasingly determining whether clinically strong assets reach patients commercially. NICE in the UK, G-BA in Germany, and HAS in France each apply different evaluation frameworks to high-cost advanced therapies, and the candidates who can navigate all three with genuine evidence-generation expertise are scarce. These hires are typically made 12 to 24 months before expected approval. Companies that hire reactively after regulatory decisions arrive at launch have capability gaps.
  
  
• Drug Safety Physicians with Oncology or Advanced Therapy Depth are arguably the most contested PV profile in 2026 European pharma. The combination of a medical degree, Pharmaceutical Medicine specialisation (FFPM in the UK or a comparable qualification in Germany, the Netherlands, or Belgium), and oncology or advanced therapy clinical experience yields a small, aggressively recruited candidate pool. Companies running global oncology or cell therapy programmes routinely take 8 to 12 months to find the right physician at the director or VP level.

Funding volatility has materially changed how recruitment works in 2026, for both hiring companies and the candidates they want to hire. Three patterns are observable across our practice.

The first pattern is the compression of hiring authority cycles. Series B and Series C biotechs often hire on 3- to 6-month authority windows tied to clinical milestones or capital raises. We consistently see searches open in March, paused in June pending a Phase II readout, restarted in September with a different scope, and then closed in November once the financing round closes. The candidates affected by this are typically the senior individual contributors and director-level hires who were close to an offer when the pause hit. The companies that retain these candidates through the cycle are the ones that communicate honestly about timing and provide non-financial signals of intent, including meaningful conversations with the CEO, technical deep dives with the science team, and transparent updates on the funding process. The companies that go silent for two months consistently lose those candidates.

The second pattern is the rebalancing of contract and permanent hiring. With permanent headcount harder to authorise and clinical timelines unforgiving, more companies are using interim and contract hires for senior specialist roles than they did in 2022. Senior regulatory consultants, fractional Chief Medical Officers, and contract validation engineers have all grown as categories. From what we see across hiring processes, this is no longer a stigma for senior candidates; many actively prefer the contract route in 2026 because it allows them to run multiple programmes in parallel and avoid concentration risk with any single employer. For hiring leaders, the practical implication is that the senior talent they want is increasingly available on contract terms when it cannot be hired permanently.

The third pattern is the equity and milestone restructuring. With venture funding selective and IPO windows still partially closed, the equity offered by venture-backed biotechs in 2026 looks meaningfully different from 2021. Vesting schedules are often extended, milestone gates are more concrete, and senior offers increasingly include explicit clauses around what happens if the company is acquired or restructured. Strong candidates are negotiating these terms harder than they used to. The hiring leaders who close offers in 2026 are those who have thought through the equity structure carefully before going to offer, rather than treating it as a finance team afterthought.

The risk of a hiring strategy that doesn't adapt to funding volatility is concrete. A biotech that runs its hiring like the funding will close on schedule, and the milestones will hit on time, and treats every search as if it can be paused and restarted at no cost, ends up with longer time-to-fill, weaker shortlists, and meaningfully higher hiring spend per closed search. The companies that build flexibility, transparency, and equity sophistication into their recruitment strategy are the ones converting their funding into actual capability.

What are the biggest hiring challenges in pharma and biotech in 2026?

Five challenges interact with each other: candidate caution after three years of high-profile layoffs (offers that would have closed in two weeks in 2021 now take six to eight); funding-driven volatility within individual companies (hiring authority can shift between search opening and closing); the specialist-versus-generalist split (overall postings down ~8% but specific specialist roles in acute demand); the AI and digital literacy gap (ABPI reports 43% of pharma companies struggle to find candidates with required digital skills); and European cluster competition concentrated in Basel, Cambridge-Oxford-London, Amsterdam, Mainz, Munich, Heidelberg, Copenhagen, and Dublin. The companies treating the market as a single signal pay for that simplification with delayed hires.

Which roles are hardest to fill in European life sciences?

Six categories dominate hard-to-fill 2026 European searches: Senior CMC Leaders for Cell and Gene Therapy (demand exceeds supply by approximately 4 to 1, searches typically take 6-9 months); AI-aware Regulatory Affairs and Quality Leaders (driven by EU AI Act, EMA Annex 22, and FDA-EMA joint AI principles); Qualified Persons for Pharmacovigilance (the longest-running senior PV shortage); Computational Biologists and ML Scientists for Drug Discovery (where AI-native biotechs and pharma AI labs compete for the same candidates); Market Access and HEOR Leaders for rare disease and advanced therapy; and Drug Safety Physicians with oncology or advanced therapy depth (8-12 months to close at director or VP level).

How is funding volatility affecting recruitment strategies?

Three patterns dominate. First, hiring authority cycles have compressed. Series B and Series C biotechs often run searches with 3-6-month authority windows tied to clinical milestones or capital raises, and the companies that retain candidates through pauses are those that communicate honestly. Second, contract and interim hiring have rebalanced senior regulatory consultants, fractional CMOs, and contract validation engineers, all of which are expanded categories, and senior candidates increasingly prefer the contract route. Third, equity offers have restructured vesting schedules, more concretely extended milestone gates, and acquisition and restructuring clauses have been negotiated more aggressively. Hiring leaders who treat funding volatility as an integral part of their recruitment strategy outperform those who treat it as an external complication.

Pharma and biotech hiring in 2026 is a barbell market: macro restraint and aggressive specialist competition running simultaneously, depending on the role and the company segment. The hiring leaders winning this environment are not the ones reading the market as either 'hot' or 'cold'; they are the ones who have understood that the layoff narrative and the talent shortage narrative are both true, applied to different parts of the same industry. Recruitment strategies that worked in the easy-money years of 2020 and 2021 do not work in 2026, and the companies still running them are paying for that mismatch with longer time-to-fill, weaker shortlists, and offers that arrive at the wrong number. The companies that have adapted are converting their funding into capability faster than their competitors.